Biotechnology company Amgen Inc on Thursday said its third-quarter revenue rose 1% as sales volume growth for its cancer, rheumatology and cardiovascular products was somewhat offset by lower prices and foreign exchange losses.
Revenue for the quarter totaled $6.7 billion, exceeding Wall Street estimates of $6.56 billion, as compiled by Refinitiv.
Adjusted earnings per share increased to $4.70 from $4.08 a year earlier, beating analyst estimates of $4.42.
Net income rose 14% to $2.14 billion.
For the full year, Amgen narrowed its outlook for adjusted earnings per share to a range of $17.25 to $17.85 on revenue of $26 billion to $26.3 billion, from its previous forecast of $17 to $18 per share on revenue of $25.5 billion to $26.4 billion.
https://finance.yahoo.com/news/refile-amgen-posts-higher-third-201512933.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.